The insider purchase is too small to signal strong conviction; focus on the upcoming Phase 3 trial initiation for urcosimod, which is the primary catalyst. Monitor for enrollment updates and any financing needs given the pre-revenue stage.
Price Chart
Executive Summary
OKYO Pharma disclosed that Non-Executive Director John Brancaccio purchased 5,000 ordinary shares at $1.48 per share on Nasdaq, increasing his total holdings to 35,201 shares. The $7,400 purchase is a routine insider transaction and does not materially alter the company's financial outlook or near-term catalysts.
Key Facts
- Non-Executive Director John Brancaccio bought 5,000 shares at $1.48 per share on July 23, 2026.
- Total director holdings increased to 35,201 shares.
- OKYO is a clinical-stage biopharma planning a global Phase 3 pivotal trial for urcosimod in neuropathic corneal pain in H2 2026.
Financial Impact
Purchase value of approximately $7,400 — immaterial relative to $49M market cap.
Risk Factors
- Clinical trial failure or delay for urcosimod Phase 3.
- Dilution risk from potential future equity offerings (referenced F-3 shelf registration).
- Limited cash runway and ongoing operating losses typical of clinical-stage biotechs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-034362 |
| Exhibit: ex99-1.htm | 0001493152-26-034362 |
| Document: 0001493152-26-034362-index-headers.html | 0001493152-26-034362 |
| Document: 0001493152-26-034362-index.html | 0001493152-26-034362 |
| Document: 0001493152-26-034362.txt | 0001493152-26-034362 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.49 (+2.05%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.49 (+9.56%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.49 (−2.61%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.49 (−5.10%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.49 (−9.15%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.49 (−9.15%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.49 (+0.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers